A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study

Olaf van Tellingen(Dutch Cancer Society), Jos H. Beijnen(The Netherlands Cancer Institute), Cornelis J. A. Punt(Radboud University Nijmegen), D. J. Theo Wagener(The Netherlands Cancer Institute), R.E.C. Henrar(European Organisation for Research and Treatment of Cancer), Y. Groot, Martine Piccart(Université Libre de Bruxelles), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), W J Nooijen, Larry J. Schaaf(Georgetown University)
Cancer Chemotherapy and Pharmacology
February 25, 1998
10.1007/s002800050754
Cited by 11

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k